Tiletamine–zolazepam combines two pharmacologically distinct compounds. Tiletamine is a dissociative anesthetic related to ketamine and acts primarily as an antagonist of N-methyl-D-aspartate, or NMDA, receptors. These receptors normally respond to the neurotransmitter glutamate and help regulate learning, memory, sensory processing and synaptic plasticity. Blocking them can disrupt the brain’s integration of sensory information, producing dissociation, altered perception and impaired motor control. Zolazepam is a benzodiazepine that enhances the activity of gamma-aminobutyric acid, or GABA, the brain’s main inhibitory neurotransmitter. The combination is used in veterinary medicine because its complementary actions can produce reliable sedation and anesthesia, but the same effects can become dangerous when the drug is used outside medical supervision.

The researchers reviewed the clinical presentations, laboratory results and brain-imaging findings of patients admitted with Zoletil 50 toxicity, then assessed outcomes during a prospective two-year follow-up. The most consistent abnormality was tremor: all 36 patients showed postural tremor, meaning that shaking became apparent when a limb or body part was held against gravity. In 22 patients, or 61.1 percent, the tremor was sustained and high in amplitude during the early period after hospital admission. Such shaking can reflect dysfunction in neural circuits linking the cerebellum, brainstem and motor regions of the cerebral cortex. Four patients, representing 11 percent of the group, developed bradykinesia and rigidity—slowness of movement and increased muscle tone—symptoms that resemble parkinsonian disorders and suggest that exposure may affect circuits extending beyond the cerebellum.

Cerebellar ataxia occurred in 30 patients, or 83 percent of the cohort. The cerebellum continuously compares intended movements with sensory feedback and adjusts muscle activity so that actions remain precise. Disruption of this system can cause an unsteady gait, inaccurate limb movements, difficulty standing and impaired coordination of speech or eye movements. Visual disturbances were reported by 20 patients, or 56 percent, and 16 patients, or 44 percent, experienced hallucinations alongside their other symptoms. The combination of ataxia, visual changes and perceptual disturbances could make patients particularly vulnerable to falls, accidents and misdiagnosis, especially when exposure is not disclosed or cannot be confirmed by routine laboratory tests.

The toxicity was not confined to the nervous system. More than half of the patients, 53 percent, had elevated transaminases, enzymes commonly used as indicators of liver-cell injury. Another 44 percent developed hypokalemia, an abnormally low concentration of potassium in the blood. Potassium is essential for maintaining the electrical gradients that allow nerve and muscle cells—including cardiac muscle—to function. Severe hypokalemia can contribute to muscle weakness and cardiac rhythm disturbances, although the study does not establish that it directly caused any particular outcome in these patients. Two people died in hospital from cardiorespiratory failure, underscoring the possibility that intoxication can progress from neurological disturbance to life-threatening disruption of breathing and cardiovascular function.

The follow-up data revealed a striking pattern of relapse. Of the 34 patients discharged from hospital, 20—59 percent—returned to using the drug. Seventeen of those relapses occurred within the first month, indicating that the period immediately after acute treatment may be especially hazardous. One additional patient died during follow-up after a fifth relapse. Because the study was retrospective and did not include a comparison group, it cannot determine precisely why relapse was so common or prove that every long-term deficit was caused solely by Zoletil exposure. Nevertheless, the repeated episodes and their timing provide clinical evidence that the problem involves more than a single episode of intoxication. Dependence, reinforcement from dissociative effects, social access to the drug and untreated psychiatric symptoms could all contribute, but the study did not test these explanations directly.

Among 33 survivors assessed at two years, 11 still had neurological problems. Seven reported subjective memory decline, six continued to experience visual impairment and two had persistent bradykinesia severe enough to require levodopa, a medication commonly used to increase dopamine signaling in the treatment of parkinsonian symptoms. These residual effects suggest that recovery from acute intoxication is not guaranteed. Several biological mechanisms could potentially account for prolonged injury, although the researchers emphasize that prospective controlled studies are needed. Chronic disruption of NMDA signaling can produce compensatory changes in receptor systems, while prolonged benzodiazepine exposure can alter GABA-related signaling. Experimental work cited by the authors has also associated Zoletil with oxidative stress and inflammatory responses in microglial cells, the immune cells of the central nervous system. These findings are mechanistic clues rather than proof of the exact process occurring in exposed humans.

The study also highlights a challenge for emergency and neurological care: tiletamine–zolazepam may be invisible to standard toxicology panels. Clinicians evaluating a young patient with unexplained tremor, ataxia, hallucinations or visual disturbance may therefore need to ask specifically about veterinary anesthetic use and consider specialized testing. Earlier reports have documented movement disorders, psychosis and fatal poisoning involving tiletamine-containing products, while newer reports have described severe tremors after tiletamine-containing electronic cigarettes. The current case series broadens that picture by linking recreational inhalation with multisystem injury and by documenting outcomes over an extended period. Its findings do not establish the prevalence of Zoletil misuse, identify a safe exposure threshold or demonstrate that inhalation is less dangerous than other routes. They do, however, show that a drug designed to immobilize animals can leave human users with persistent neurological harm, repeated relapse and, in some cases, fatal cardiorespiratory failure.